Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03150056 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT03150056 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 73 participants.
The verdict
NCT03150056, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B).
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG GSK525762
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2021-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03150056
The ClinicalTrials.gov registry entry for NCT03150056 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT03150056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03150056 about?
NCT03150056 is a clinical study titled "Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer". This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pha...
What is the current status of trial NCT03150056?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2017-07-18. Estimated completion is 2021-06-22.
What interventions are being tested in trial NCT03150056?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), GSK525762 (DRUG).
Who is sponsoring clinical trial NCT03150056?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.